Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 5 studies | 25% ± 6% | |
glutamatergic neuron | 4 studies | 30% ± 15% | |
retinal ganglion cell | 3 studies | 35% ± 14% | |
neuron | 3 studies | 20% ± 6% |
Insufficient scRNA-seq data for expression of CHST8 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 856.00 | 2559 / 2642 | 90% | 10.83 | 634 / 705 |
prostate | 57% | 64.85 | 140 / 245 | 85% | 3.25 | 427 / 502 |
breast | 58% | 182.43 | 268 / 459 | 69% | 14.35 | 776 / 1118 |
adrenal gland | 15% | 31.52 | 39 / 258 | 75% | 25.15 | 173 / 230 |
spleen | 83% | 126.71 | 201 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 4.91 | 66 / 80 |
ovary | 69% | 86.88 | 124 / 180 | 8% | 0.56 | 35 / 430 |
uterus | 46% | 45.02 | 78 / 170 | 17% | 1.44 | 79 / 459 |
pancreas | 22% | 21.21 | 73 / 328 | 35% | 1.93 | 63 / 178 |
thymus | 47% | 46.46 | 304 / 653 | 5% | 0.30 | 31 / 605 |
adipose | 32% | 38.74 | 382 / 1204 | 0% | 0 | 0 / 0 |
bladder | 10% | 6.90 | 2 / 21 | 19% | 1.51 | 94 / 504 |
blood vessel | 27% | 31.83 | 362 / 1335 | 0% | 0 | 0 / 0 |
intestine | 16% | 13.88 | 154 / 966 | 4% | 0.17 | 23 / 527 |
esophagus | 12% | 10.56 | 172 / 1445 | 4% | 0.10 | 8 / 183 |
lung | 5% | 4.45 | 30 / 578 | 10% | 0.53 | 113 / 1155 |
skin | 4% | 4.20 | 67 / 1809 | 10% | 0.57 | 46 / 472 |
liver | 1% | 1.14 | 3 / 226 | 12% | 1.09 | 48 / 406 |
stomach | 9% | 11.05 | 31 / 359 | 3% | 0.08 | 10 / 286 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.32 | 3 / 29 |
tonsil | 0% | 0 | 0 / 0 | 7% | 0.13 | 3 / 45 |
heart | 6% | 5.42 | 53 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 4% | 4.30 | 35 / 929 | 0% | 0 | 0 / 0 |
kidney | 0% | 0 | 0 / 89 | 2% | 0.29 | 16 / 901 |
muscle | 0% | 0.36 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042446 | Biological process | hormone biosynthetic process |
GO_0030166 | Biological process | proteoglycan biosynthetic process |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0016051 | Biological process | carbohydrate biosynthetic process |
GO_0007417 | Biological process | central nervous system development |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016020 | Cellular component | membrane |
GO_0001537 | Molecular function | N-acetylgalactosamine 4-O-sulfotransferase activity |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CHST8 |
Protein name | Carbohydrate sulfotransferase 8 (EC 2.8.2.-) (GalNAc-4-O-sulfotransferase 1) (GalNAc-4-ST1) (GalNAc4ST-1) (N-acetylgalactosamine-4-O-sulfotransferase 1) Carbohydrate sulfotransferase 8 |
Synonyms | |
Description | FUNCTION: Catalyzes the transfer of sulfate to position 4 of non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans. Required for biosynthesis of glycoprotein hormones lutropin and thyrotropin, by mediating sulfation of their carbohydrate structures. Only active against terminal GalNAcbeta1,GalNAcbeta. Not active toward chondroitin. . |
Accessions | ENST00000438847.7 ENST00000591231.5 ENST00000434302.5 ENST00000262622.4 K7ENM3 ENST00000650847.1 Q9H2A9 |